Incannex HealthcareIXHL
IXHL
About: Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
Employees: 9
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0.09% less ownership
Funds ownership: 1.91% [Q4 2024] → 1.82% (-0.09%) [Q1 2025]
14% less funds holding
Funds holding: 7 [Q4 2024] → 6 (-1) [Q1 2025]
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
53% less capital invested
Capital invested by funds: $714K [Q4 2024] → $339K (-$375K) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for IXHL.
Financial journalist opinion
Based on 7 articles about IXHL published over the past 30 days
Neutral
GlobeNewsWire
3 days ago
Incannex Healthcare Cancels All Outstanding Series A Warrants Following Strategic ATM Execution
Capital structure streamlined and potential dilution from Series A Warrants eliminated ahead of key Phase 2 clinical milestones Capital structure streamlined and potential dilution from Series A Warrants eliminated ahead of key Phase 2 clinical milestones
Neutral
GlobeNewsWire
1 week ago
Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program
NEW YORK and MELBOURNE, Australia, June 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today announced the recent appointment of four distinguished experts to its IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board:
Neutral
GlobeNewsWire
2 weeks ago
Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance
NEW YORK and MELBOURNE, Australia, May 29, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage pharmaceutical company developing novel combination therapies, today announced that the Phase 3 component of the RePOSA clinical trial will proceed. The U.S. Food and Drug Administration (FDA) previously reviewed and authorized the protocol to proceed under the Company's Investigational New Drug (IND) application.
Neutral
Newsfile Corp
2 weeks ago
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025
Dallas, Texas--(Newsfile Corp. - May 28, 2025) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). During the third quarter of fiscal year 2025, IXHL reported R&D expenses of $2.74M, down from $3.28M in the same quarter of the previous year, reflecting cost containment measures.
Neutral
GlobeNewsWire
2 weeks ago
Incannex Healthcare Inc. Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of IHL-42X Phase 2 Topline Results
MELBOURNE, Australia and NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, today announced that it has entered into a binding agreement to cancel the remaining 172 million Series A Warrants issued under a previous financing arrangement contingent upon Incannex paying the Series A Warrant holders a cancellation payment of up to $12.2 million. When combined with the earlier tranche canceled earlier this month, this agreement will result in the elimination of up to 347.2 million shares from potential future dilution, pending final execution.
Neutral
GlobeNewsWire
3 weeks ago
Incannex Healthcare Inc. Executes Strategic Cancellation of 50.4% of Series A Warrants, Significantly Reducing Potential Dilution
Raises $12.5M via ATM to Strengthen Shareholder Position Ahead of IHL-42X Phase 2 Data Raises $12.5M via ATM to Strengthen Shareholder Position Ahead of IHL-42X Phase 2 Data
Neutral
GlobeNewsWire
4 weeks ago
Incannex Announces Potential Reduction of Up to 50.4% of its Series A Warrants
NEW YORK and MELBOURNE, Australia, May 16, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (“Incannex”), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, announced its entry on May 15, 2025 into agreements with the outstanding holders of its Series A Warrants (the “Letter Agreements”) permitting Incannex to potentially reduce up to 50.4% of the shares of common stock underlying its previously issued Series A Warrants.
Neutral
GlobeNewsWire
1 month ago
Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates
NEW YORK and MELBOURNE, Australia, May 15, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today reported fiscal second quarter financial results and provided business highlights for the quarter ended March 31, 2025. “The third quarter of 2025 represents a pivotal period of progress for Incannex as we continue to execute on our IHL-42X development program,” said Joel Latham, President and CEO of Incannex.
Positive
Benzinga
1 month ago
Incannex Healthcare (IXHL) Stock Soars Over 800%: What's Going On?
Incannex Healthcare Inc IXHL shares surged 876% to 83 cents on Wednesday after the company announced the completion of patient dosing in the Phase 2 portion of its Phase 2/3 RePOSA trial for IHL-42X, an investigational oral treatment for obstructive sleep apnea (OSA).
Neutral
GlobeNewsWire
1 month ago
Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)
Patient dosing completed in Phase 2 portion of Phase 2/3 RePOSA study evaluating IHL-42X oral treatment for OSA. End-of-study follow-up assessments on track for completion by May 17, 2025.
Charts implemented using Lightweight Charts™